| Fund ID | 805-6495046271 |
| Fund type | Hedge Fund |
| 3(c)(1) exclusion | No |
| 3(c)(7) exclusion | Yes |
| Master fund | No |
| Feeder fund | No |
| Fund of funds | No |
| Relies on exemption from registration | Yes |
| Annual audit | Yes |
| Prepared per GAAP | Yes |
| Sub-advised | No |
| % of assets independently valued | 100% |
| Owned by the adviser or related persons | 0% |
| Owned by funds of funds | 0% |
| Owned by non-U.S. persons | 0% |
| Fund | Type | Gross assets |
|---|---|---|
| Obsidian Relative Value Strategy Master Fund, Ltd. | Hedge | $14.14B |
| BlackRock Long Term Private Capital Scsp | Hedge | $10.59B |
| Current Asset Fund Limited | Liquidity | $6.75B |
Biomedical Innovation Opportunities Ltd. reports $23.5 million in gross assets, among the top 66% of private funds by size.
The stated minimum investment is $1 million.
Biomedical Innovation Opportunities Ltd. is managed by BlackRock Financial Management, Inc.
No. Private funds are not required to publicly disclose performance. Form ADV reports assets, structure, and service providers.